OTC · NMTRQ
9 Meters Biopharma, Inc.
$0.00$0.00 (0.0%)
9 Meters Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
Loading market information…
OTC · IMVIF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
IMV Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$1.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IMV Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers. The flagship therapeutic, maveropepimut-S, is an immunotherapy derived from the DPX platform, specifically engineered to attack cells expressing survivin. This compound is currently advancing through Phase II clinical studies for diffuse large B-cell lymphoma, ovarian cancer, and a variety of solid tumors including those affecting the bladder, liver, and MSI-H positive types. It is also in Phase I investigation for breast cancer. Additionally, the company's pipeline includes DPX-SurMAGE, undergoing Phase I clinical evaluation for bladder cancer, alongside the development of DPX-COVID-19 and DPX-RSV for addressing infectious diseases. The entity, previously known as Immunovaccine Inc., formally adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its corporate headquarters in Dartmouth, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2019 |
|---|
| Mar 30, 2020 |
| -$1.29-12.99% vs estimate |
| $33.90K-46.33% vs estimate |
| Q1 2019 | Apr 1, 2019 | -$1.25-28.46% vs estimate | $32.89K-45.75% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
9 Meters Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
BIMI International Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
DMK Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00-$0.00 (0.0%)
Omnimmune Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
eFFECTOR Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
Minerva Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
Proteonomix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Adhera Therapeutics Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
